1. Home
  2. Material Detail: Immunotherapy for Glioblastoma: Current Progress and Challenges

Material Detail

"Immunotherapy for Glioblastoma: Current Progress and Challenges" icon

Immunotherapy for Glioblastoma: Current Progress and Challenges

Glioblastoma is a highly lethal brain cancer with a median survival rate of less than 15 months when treated with the current standard of care, which consists of surgery, radiotherapy and chemotherapy.

Disciplines:
Go to Material 
Bookmark / Add to Course ePortfolio
Create a Learning Exercise
Add Accessibility Information
Rate
Add a Comment

Quality

  • User Rating
  • Comments
  • Learning Exercises
  • Bookmark Collections
  • Course ePortfolios
  • Accessibility Info

More about this material

Material Type:
Open (Access) Journal-Article
Date Added to MERLOT:
July 23, 2024
Date Modified in MERLOT:
August 15, 2024
Author:
Unknown (Know the author?)
Submitter:
Lydia Granados
Primary Audience:
High School, College General Ed, College Lower Division, College Upper Division, Graduate School, Professional
Technical Format:
Website
Mobile Compatibility:
Not specified at this time
Language:
English
Cost Involved:
Unknown
Source Code Available:
Yes
Creative Commons:
Unknown

Browse...

Disciplines with similar materials as Immunotherapy for Glioblastoma: Current Progress and Challenges
People who viewed this also viewed
Other materials like Immunotherapy for Glioblastoma: Current Progress and Challenges

Comments

Log in to participate in the discussions or sign up if you are not already a MERLOT member.